Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

GI Videos

Anant Ramaswamy, MD, on the Efficacy of Capecitabine-Irinotecan vs Irinotecan for Advanced Gallbladder Cancer
Videos
Anant Ramaswamy, MD, on the Efficacy of Capecitabine-Irinotecan vs Irinotecan for Advanced Gallbladder Cancer
07/01/2020
Dr Ramaswamy provides perspective on a phase 2 trial comparing the efficacy of irinotecan administered with or without capecitabine for advanced gallbladder cancer.
Dr Ramaswamy provides perspective on a phase 2 trial comparing the efficacy of irinotecan administered with or without capecitabine for advanced gallbladder cancer.
Dr Ramaswamy provides...
07/01/2020
Oncology
Axel Grothey, MD, Talks About the Upcoming ESMO World Congress on GI Cancer
Videos
Axel Grothey, MD, Talks About the Upcoming ESMO World Congress on GI Cancer
06/22/2020
Dr Grothey tells us what we can look forward to at the 22nd ESMO World Congress on Gastrointestinal Cancer, which is taking place virtually this year.
Dr Grothey tells us what we can look forward to at the 22nd ESMO World Congress on Gastrointestinal Cancer, which is taking place virtually this year.
Dr Grothey tells us what we can...
06/22/2020
Oncology
Solange Peters, MD, PhD, on What to Expect at the Virtual ESMO World Congress on GI Cancer
Videos
Solange Peters, MD, PhD, on What to Expect at the Virtual ESMO World Congress on GI Cancer
06/21/2020
The President of ESMO discusses what attendees of the annual ESMO World Congress on GI Cancer can expect from the virtual 2020 event.
The President of ESMO discusses what attendees of the annual ESMO World Congress on GI Cancer can expect from the virtual 2020 event.
The President of ESMO discusses...
06/21/2020
Oncology
Overcoming COVID-19 Hurdles in Routine Clinical Practice
Videos
Overcoming COVID-19 Hurdles in Routine Clinical Practice
04/16/2020
Axel Grothey, MD, talks about how healthcare providers are rising to face the challenges presented by the COVID-19 pandemic in routine clinical practice.
Axel Grothey, MD, talks about how healthcare providers are rising to face the challenges presented by the COVID-19 pandemic in routine clinical practice.
Axel Grothey, MD, talks about...
04/16/2020
Oncology
How I Practice Now: Benefits of Telemedicine Today and Going Forward
Videos
How I Practice Now: Benefits of Telemedicine Today and Going Forward
04/01/2020
Axel Grothey, MD, discusses how telemedicine is allowing healthcare providers and patients to adapt during the COVID-19 crisis.
Axel Grothey, MD, discusses how telemedicine is allowing healthcare providers and patients to adapt during the COVID-19 crisis.
Axel Grothey, MD, discusses how...
04/01/2020
Oncology
Axel Grothey, MD, Talks COVID-19 and the Provision of Cancer Care
Videos
Axel Grothey, MD, Talks COVID-19 and the Provision of Cancer Care
03/28/2020
Dr Grothey talks about the impact that the COVID-19 pandemic has had on the treatment of patients with cancer.
Dr Grothey talks about the impact that the COVID-19 pandemic has had on the treatment of patients with cancer.
Dr Grothey talks about the...
03/28/2020
Oncology
Videos
Ivosidenib Shows Clinical Benefit in IDH1-Mutant Advanced Cholangiocarcinoma
10/23/2019
Ghassan Abou-Alfa, MD, MBA, discusses the results from the ClarIDHy trial, which show the potential for ivosidenib as a new standard for patients with IDH1-mutant advanced cholangiocarcinoma.
Ghassan Abou-Alfa, MD, MBA, discusses the results from the ClarIDHy trial, which show the potential for ivosidenib as a new standard for patients with IDH1-mutant advanced cholangiocarcinoma.
Ghassan Abou-Alfa, MD, MBA,...
10/23/2019
Oncology
Videos
The Role of ctDNA in Gastrointestinal Cancer
10/16/2019
Scott Kopetz, MD, PhD, FACP, discusses the role of circulating tumor DNA (ctDNA) in gastrointestinal cancer.
Scott Kopetz, MD, PhD, FACP, discusses the role of circulating tumor DNA (ctDNA) in gastrointestinal cancer.
Scott Kopetz, MD, PhD, FACP,...
10/16/2019
Oncology
Videos
Pembrolizumab Effective Treatment Option for MSI-H Gastric Cancer
09/29/2019
Kohei Shitara, MD, discusses the use of pembrolizumab with or without chemo in patients with advanced gastric cancer, including MSI-H disease.
Kohei Shitara, MD, discusses the use of pembrolizumab with or without chemo in patients with advanced gastric cancer, including MSI-H disease.
Kohei Shitara, MD, discusses the...
09/29/2019
Oncology
Videos
PARP Inhibitor Maintenance Therapy for Pancreatic Cancer With BRCA Mutation
09/14/2019
Eileen O'Reilly, MD, debates in favor of using PARP inhibitors as maintenance therapy for BRCA mutation–positive pancreatic cancer.
Eileen O'Reilly, MD, debates in favor of using PARP inhibitors as maintenance therapy for BRCA mutation–positive pancreatic cancer.
Eileen O'Reilly, MD, debates in...
09/14/2019
Oncology

Advertisement

Advertisement

Advertisement

Recent News

News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement